

## Limited impact of COVID-19

Currently the COVID-19 outbreak continues to evolve rapidly, with governmental guidance changing every day. At Orexo, our priority remains to ensure the wellbeing and safety of our employees, patients and our partners. We are monitoring the development of this situation closely, and based on currently available information suggesting that COVID-19 will likely reach a peak in late spring, we see it can cause some delays within our development chain, resulting in unexpected delays in our pharmaceutical projects. To try to avoid any delivery delays we are working proactively and closely with several parties across different geographies to assess future activities. For other areas in our company, such as the supply chain and sales, but also for our financial development, we currently see limited impact. We will continue to assess the situation and will be providing a further update in our Q1 report scheduled on April 28, 2020.

March 24, 2020

Nikolaj Sørensen

President and CEO